{
    "id": "correct_subsidiary_00046_2",
    "rank": 71,
    "data": {
        "url": "https://www.slideshare.net/slideshow/glaxosmithkline-15376694/15376694",
        "read_more_link": "",
        "language": "en",
        "title": "GlaxoSmithKline",
        "top_image": "https://cdn.slidesharecdn.com/ss_thumbnails/gsk-121127165335-phpapp01-thumbnail.jpg?width=640&height=640&fit=bounds",
        "meta_img": "https://cdn.slidesharecdn.com/ss_thumbnails/gsk-121127165335-phpapp01-thumbnail.jpg?width=640&height=640&fit=bounds",
        "images": [
            "https://public.slidesharecdn.com/images/next/logo-slideshare-scribd-company.svg?w=128&q=75 1x, https://public.slidesharecdn.com/images/next/logo-slideshare-scribd-company.svg?w=256&q=75 2x",
            "https://cdn.slidesharecdn.com/profile-photo-PriyeshWaghmare-48x48.jpg?cb=1523006554",
            "https://image.slidesharecdn.com/gsk-121127165335-phpapp01/85/GlaxoSmithKline-1-320.jpg 320w, https://image.slidesharecdn.com/gsk-121127165335-phpapp01/85/GlaxoSmithKline-1-638.jpg 638w, https://image.slidesharecdn.com/gsk-121127165335-phpapp01/75/GlaxoSmithKline-1-2048.jpg 2048w"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2012-11-27T16:53:35+00:00",
        "summary": "",
        "meta_description": "GlaxoSmithKline - Download as a PDF or view online for free",
        "meta_lang": "en",
        "meta_favicon": "https://public.slidesharecdn.com/_next/static/media/favicon.7bc3d920.ico",
        "meta_site_name": "SlideShare",
        "canonical_link": "https://www.slideshare.net/slideshow/glaxosmithkline-15376694/15376694",
        "text": "•Download as PPTX, PDF•\n\n7 likes•11,135 views\n\nGlaxoSmithKline plc is a global pharmaceutical company headquartered in London, UK. It is the 3rd largest pharmaceutical company by revenue and has leading market share in anti-infectives, central nervous system, respiratory, and gastrointestinal drugs. GSK spends over $450,000 per hour on research and development and has acquired several companies in recent years to expand its product portfolio. The company's business model focuses on several therapeutic areas with respiratory, central nervous system, and vaccines being the largest segments by revenue.\n\nGlaxoSmithKline\n\n2. INTRODUCTION •Global pharmaceutical, biologics, vaccines and consumer healthcare company •3rd largest pharmaceutical company in the world based on revenues •Leading market share in 4 of the 5 largest therapeutic markets-- anti- infective , central nervous system, respiratory, and gastro- intestinal/metabolic. •5 % of the global pharmaceuticals market. •1,100 prescriptions are written for one of its products every minute. •Spends over $450,000 every hour on R & D.\n\n3. COMPANY PROFILE •Headquarters: London, UK •Employee Strength: 96,500 •Global operations: Over 100 countries •Stock Listing: Primary - London Stock Exchange Secondary – New York Stock Exchange •Revenue (2010): £ 28.4 billion\n\n5. COMPANY EVOLUTION GlaxoWellcome SmithKline Beecham • Beecham Pills laxative in England • In 1880, Burroughs Wellcome & gave birth to the Beecham Group Company was founded in London – in 1843. • Smith, Kline & Co founded in research in animal health 1875 – pure research • Glaxo was founded in Bunnythorpe, • 1989 merged with Beecham to form SmithKline Beecham plc. New Zealand in 1904 – baby food producer • Burroughs Wellcome and Glaxo merged in 1995 to form GlaxoWellcome\n\n7. RECENT ACQUISITIONS • In 2001 it completed its purchase of New Jersey-based Block Drug. • On 16 November 2009 the US FDA announced that a vaccine for 2009 H1N1 influenza protection (manufactured by GSK's ID Biomedical Corp. subsidiary) would join the four approved vaccines. • In November 2009 GlaxoSmithKline (85%) formed a joint venture with Pfizer (15%) to create ViiV Healthcare for HIV based drugs. • In June 2010, the company acquired Laboratorios Phoenix for $253m, which is an Argentine pharmaceutical company focused on the development, marketing and sale of branded generic products. • In December 2010, GSK announced its acquisition of the sports nutrition company Maxinutrition.\n\n8. BUSINESS MODEL\n\n9. GSK Medicinal Products Therapeutic Area Turnover 2010 £m Respiratory 7,238 Central nervous system 1,753 Anti-viral 1,086 Anti-bacterials 1,396 Metabolic 678 Vaccines 4,326 Oncology and emesis 688 Cardiovascular and 2,570 urogenital Dermatologicals 1,087 Other 994 Total 21,816\n\n10. Bexxar • Drug for the treatment of follicular lymphoma • Drug combination is manufactured by Corixa • Received US Food and Drug Administration approval in mid- 2003 • GlaxoSmithKline acquired Corixa in mid-2005 • Charges - $30,000 dollars a treatment • Currently involved in 9 EU clinical trials testing efficacy and safety ranging from phase III to phase I\n\n11. Lexiva • HIV protease inhibitor • Co-developed the drug with Vertex Pharmaceuticals Incorporated. • U.S. Approval: 2003 • Got approval in EU market in July 2004. • Marketed as Telzir EU at approx £9/unit • Lexiva global sales in 2010 were £155 million\n\n12. Cervarix • Treatment against Human Papillomaviruses (HPV) infection • European Approval in September 2007 • FDA approval October 2009 • Approved and marketed in 99 countries including most of the major markets like US, Europe, Japan, China, India, Brazil, South Africa • Cervarix global sales in 2010 were £242 million\n\n13. GSK Biopharmaceuticals • A strategic unit within GSK’s Global Manufacturing & Supply network • Located in Philadelphia, USA; Parma, Italy and Barnard Castle, UK. • Undertakes Contract manufacturing partner • FDA and European licensed multi-product facilities."
    }
}